Proton pump inhibitors (PPIs) have been established as the new "gold standard" for traditional acid-inhibitory treatment of the so called "peptic" diseases. Due to the high antisecretory and ulcer-healing potency of omeprazole, no major improvements of the efficacy in ulcer healing and pain relief can be expected. Pantoprazole, as a further development in PPIs, is characterized by improved pharmacokinetic behavior as well as by higher tissue selectivity and binding specificity and by a very low potential to interact with the cytochrome P40 enzyme system. These characteristics may provide the basis for a low potentlal for side effects and for a more favorable interaction profile, although the clinical relevance of these potential advantages remains to be proven. Reflux esophagitis will also remain a domain for the traditional use of PPIs in the future. However, in the treatment of gastroduodenal ulcers, the acid inhibitory potential of PPIs will be used mainly to facilitate the eradication of H. pylori.
INTRODUCTION
Since Schwarz's dictum "no acid -no ulcer" was coined in 1910 [1] , treatment of reflux esophagitis and gastro-duodenal ulcers has been awaiting modalities providing effective control of gastric acid secretion. It was not until the late 1960s that antacids became available. These, however, just partially neutralized gastric acid that already had been secreted. Thus, symptom control and healing rates were unsatisfactory. These disappointing results, together with the inconvenience of frequent drug intake, resulted in poor patient compliance.
It was only logical that antacids were rapidly replaced by antagonists acting at the parietal cell histamine H2 receptors. For the first time these drugs provided effective inhibition of production and release of gastric acid via a pharmacologically well-defined mechanism and became the gold standard of acid inhibitory therapy in the late 1970s.
However, H2 receptor antagonists (H2RAs)b do not block parietal cell stimulation by agonists other than histamine, e.g., vagal acetylcholine interacting with parietal cell M3 receptors. Moreover, H2RAs are far more effective in inhibiting nocturnal than day-time acid secretion. Furthermore, the efficacy of these drugs declines after several days of treatment.
These shortcomings were overcome when proton pump inhibitors (PPIs) became available for clinical use in the late 1980's. Their superior antisecretory potency provided an excellent basis to replace H2RAs as the gold standard in the therapy of acid-related diseases. In the following, clinical results of treatment with PPIs, which have established these compounds as the drugs of choice, will be reviewed. Thereafter, potential advantages of further developments in PPIs will be evaluated. Finally, rationales will be discussed for the use of PPIs in a new indication, eradication of the bacterium Helicobacter pylori from the gastric mucosa.
aTo whom all correspondence should be addressed: Prof. Dr [8] [9] [10] . However, it must be kept in mind that with the later developed drugs the number of patients studied is considerably lower than with omeprazole, especially when the focus is on severe esophagitis.
Placebo-controlled studies have shown that, when treatment is stopped after healing of acute reflux esophagitis, the relapse rate is about 65 percent per year in unselected, primary-care populations [11] [12] [13] and 82 percent per six months in selected, i.e., H2RA-refractory, patients [14] . Maintenance therapy with H2RAs is not superior to placebo [11, 12, 15] and significantly less effective than prophylaxis with PPIs [11, [16] [17] [18] [19] . In a primary care population, symptomatic remission was maintained over 12 months in 72 percent, 62 percent and 45 percent of patients on 20 mg omeprazole daily, 10 mg omeprazole daily and 150 mg ranitidine twice daily, respectively [20] . The difference between the 10 and 20 mg omeprazole dose narrowly missed statistical significance (p = .06) when symptomatic relapses were evaluated [20] ; however, the higher omeprazole dose appeared to be significantly (p = .003) [20] or at least numerically [21] more effective in preventing endoscopic relapses, the remission rates after 12 months being 77 percent, 58 percent and 46 percent, respectively, for 20 mg omeprazole daily, 10 mg omeprazole daily and 150 mg ranitidine twice daily [20] . As expected, relapses are more frequent in selected, i.e., H2RA-refractory, patients apparently requiring a more intense antisecretory treatment. In these patients endoscopic remission rates of 67 percent [22] and 10-25 percent [11, 12, 15- [23] . The prophylactic effect of PPIs is independent of the grade of reflux esophagitis prior to the initial treatment, initial healing dose of PPIs, and of smoking habits [17, 23] . Continuous maintenance treatment is superior to discontinuous approaches, e.g., weekend therapy (Friday, Saturday, Sunday) [16, 19, [24] [25] [26] . In maintaining remission, the prokinetic cisapride was more effective than ranitidine but significantly less effective than omeprazole [27] . On the other hand, the efficacy of ranitidine was improved by combination with cisapride; however, even this combination was less effective than omeprazole alone, the prophylactic effect of which was not significantly increased by cisapride [27] .
Peptic strictures complicating reflux esophagitis (Savary and Miller grade IV) tend to relapse at a high frequency (about 50 percent within 12 months) [28, 29] . Following dilatation, relapse prophylaxis with H2RAs has yielded disappointing results [30, 31] . On the other hand, omeprazole (20 mg daily) reduced the need for repeat dilatation by more than 50 percent (0.48 per year) when compared to ranitidine (150 mg twice daily) (1.08 repeat dilatations per year) [32] . Omeprazole was significantly more effective than ranitidine in relieving symptoms (freedom from dysphagia (76 vs. 64 percent); acceptance of normal diet (83 vs. 69 percent); increase in median body weight (1.9 vs. 0.4 kg) [32] . This study confirmed earlier disappointing results with H2RAs and the superiority of PPIs in preventing repeat dilatation [33] .
Gastric ulcers
PPIs have been established as superior to H2RAs in the treatment of gastric ulcer. In three randomized double-blind studies [34, 35, 36] , healing rates after four and eight weeks of treatment were 73 percent and 92 percent with omeprazole 20 mg every morning, and 62 percent and 86 percent with twice-daily ranitidine according to the per-protocol analysis. Likewise, omeprazole was superior to cimetidine [37] . Continuing intake of NSAIDs resulted in slightly lower four-week healing rates with omeprazole (61 percent) and ranitidine (53 percent) [34] . Symptom relief was significantly faster in patients on omeprazole than in those on H2RAs [34] [35] [36] [37] .
With respect to healing rates and symptom relief similar superiority, over H2RAs has been observed with pantoprazole (40 mg every morning) and lansoprazole (30 mg every morning) [38, 39] while these later developed PPIs were equally effective as omeprazole [40, 41] .
Duodenal ulcers
The superiority of PPIs over H2RAs has also been established in the treatment of duodenal ulcer. According to per-protocol analysis of double-blind randomized trials, healing rates after two and four weeks of treatment were 64 percent and 92 percent with omeprazole 20 mg every morning. and 48 percent and 80 percent with ranitidine 150 mg twice daily [42] [43] [44] [45] [46] [47] [48] [49] or 300 mg at night [50] [51] [52] [53] [54] [55] [56] [57] . Likewise, omeprazole was superior to cimetidine [58] [59] [60] [61] [62] [63] . In the identical studies, omeprazole proved to be significantly more effective than H2RAs in inducing overall symptom relief as well as daytime and nighttime pain relief [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] .
A similar pattern of superiority was observed in trials comparing pantoprazole or lansoprazole with H2RAs [64, 65] . On the other hand both later developed PPIs were equally effective as omeprazole [66, 67] .
In summary, PPIs speed up the healing process of gastric and duodenal ulcers more effectively than H2RAs. The latter class of drugs is also capable of healing almost all benign gastric ulcers, however, a significantly longer time is needed to achieve healing and symptom relief. Refractory peptic lesions Esophageal, gastric and duodenal lesions that do not heal on prolonged administration or increased doses of H2RAs are regarded refractory to treatment by H2RAs. These lesions require the higher acid inhibitory potency provided by PPI treatment. Omeprazole [68] , pantoprazole [69] and lansoprazole [70] were shown to rapidly heal all H2RA-refractory peptic lesions within 12 weeks, and most of them within four weeks. Thus [72] . Effective inhibition of acid secretion in gastrinoma patients has also been reported for lansoprazole [73] , while data with pantoprazole are lacking.
NOW: ADVANTAGES OF FURTHER DEVELOPMENTS IN PPIS
Since the late 1980s omeprazole, the first PPI to be clinically used, became the new gold standard for the treatment of acid-related diseases. What advantages should further developments in substituted benzimidazoles therefore have to offer? Since the efficacy of omeprazole with respect to inhibition of acid secretion and healing rates can hardly be overcome, efficacy is unlikely to be an advantage rendering new PPIs even more attractive than omeprazole. Rather, further developments in PPIs qualify by improved pharmacokinetic properties as well as by selectivity and specificity. Pharmacokinetics
The absorption of omeprazole and lansoprazole from enteric-coated granule formulations is variable [74, 75] . Moreover, lansoprazole absorption is decreased by concomitant oral food intake [75, 76] . In contrast, pantoprazole, when directly compared with omeprazole, produced clearly smaller variations in serum concentrations after oral administration in the form of enteric-coated tablet [77, 78] . Moreover, unlike omeprazole, absorption of pantoprazole did not change after seven consecutive days of administration [77] . This holds also for the 30 and 60 mg doses, but not for the 10 and 20 mg doses of lansoprazole [79] . Thus, pantoprazole is characterized by constant pharmacokinetic parameters upon repeated once-daily dosing over one week [80] . These properties of pantoprazole and lansoprazole (at the 30 mg dose, not at other doses) are the basis for a constantly high bioavailability [80, 79] while omeprazole is characterized by a lower initial bioavailability increasing over the first week of treatment [81, 82] Although to date no PPI fulfills these ideal criteria, pantoprazole is closer than other PPIs. This drug exhibits the slowest protonation, i.e., activation, at slightly acidic levels of pH above 2, especially at pH levels up to 5.0, [87] , which may be reached temporarily in tissues others than parietal cells. In accordance with these data, in vitro activation of pantoprazole at pH above 3 levels off significantly faster than activation of omeprazole and lansoprazole [88] . As a consequence, at pH 5.0 activation of pantoprazole is down to about 25 percent while 55 percent of omeprazole and lansoprazole are still activated [88] . Likewise, the potency of pantoprazole to inhibit acid production in isolated gastric glands increases markedly with the internal acidification of the glands in response to increasingly effective stimuli, a pattern not observed with omeprazole and lansoprazole [89] . The higher selectivity of pantoprazole for the parietal cells may reduce the potential of undesired activation and side effects in other tissues, although until now no such side effects of omeprazole or lansoprazole have been identified unequivocally.
On the other hand, at the highly acidic pH levels reached in parietal cells, pantoprazole is activated at the same rate as are omeprazole and lansoprazole. Thus, the acidinhibitory capacity of pantoprazole in parietal cells is not compromised by the diminished protonation at higher pH levels. Selective binding to the proton pump Binding of radioactively labeled PPIs to trypsin-generated fragments of the H+K+-ATPase identified the cysteine residues within the enzyme molecule to which the drugs bind covalently, thereby irreversibly inhibiting the enzyme's activity. While the Cys813 residue in the membrane-spanning segment M5/M6 is the target of all three available PPIs, omeprazole (Cys892 in M7/M8) and lansoprazole (Cys892 in M7/M8 and Cys321 in M3/M4) bind to additional targets [90, 91] . Thus, binding to Cys813 in M5/M6 apparently is crucial for inhibiting the H+K+-ATPase.
To date, pantoprazole is the only PPI selectively binding to this cysteine residue. [95, 96] , an antibiotic widely used for H. pylori eradication.
Increased bioavailability of antibiotics?
Another possibility would be that PPIs and antibiotics would mutually increase their bioavailability. Again, this hypothesis was disproven. The bioavailability of amoxicillin under placebo conditions was not increased by addition of omeprazole 20 mg nor was the bioavailability of omeprazole increased by addition of amoxicillin, clarithromycin or metronidazole [95, 96] . Likewise, increasing the omeprazole dose to 40 and 80 mg had no effect on the bioavailability of amoxicillin. Increased gastric release of antibiotics?
To be active against H. pylori, antibiotics should be present at high concentrations between the gastric epithelial surface and the mucus layer. The effect of amoxicillin against H. pylori is considered mainly a systemic effect not locally provided by luminally acting drugs. Since H. pylori is rarely found within the gastric epithelium but rather on the epithelial surface directly under the mucus layer, amoxicillin would reach the highest concentration at the bacteria themselves if the gastric mucosa would actively secrete the systemically circulating drug. In fact, after i.v. injection amoxicillin is secreted into the gastric juice, the secretion being threefold increased after administration of omeprazole (40 mg twice daily.) [97] . Thus, the PPI might potentiate the amoxicillin effect against H. pylori by increasing gastric mucosal release of the antibiotic. Adjustment of gastric pH to levels appropriate for optimal activity of antibiotics?
In vitro, the activity of several antibiotics against H. pylori is increased when the pH is elevated from 5.5 to 7.5 [98, 99] . Antibiotics profit from pH elevation to differing extents. The activities of amoxicillin and some macrolides are increased by one to two orders of magnitude [98, 99] offering a possible explanation of their increased efficacy in the presence of PPIs in vivo. However, the actual pH of the microenvironment where the bacterium colonizes the gastric epithelial surface is not known. Thus, definite proof is lacking that PPIs potentiate the effect of antibiotics by adjusting the pH appropriately for optimal activity of the antibiotic, and the relevance of pH-dependent inhibitory antimicrobial drug concentrations in vitro remains to be determined. SUMMARY PPIs have been established as the new "gold standard" for traditional acid-inhibitory treatment of the so called "peptic" diseases. Due to the high antisecretory and ulcer-healing potency of omeprazole, no major improvements of the efficacy in ulcer healing and pain relief can be expected. Pantoprazole, as a further development in PPIs, is characterized by improved pharmacokinetic behavior as well as by higher tissue selectivity and binding specificity and by a very low potential to interact with the cytochrome P450 enzyme system. These characteristics may provide the basis for low potential for side effects and for more favorable interaction profile, although the clinical relevance of these potential advantages remains to be proven. Reflux esophagitis will remain a domain for the traditional use of PPIs also in the future. However, in the treatment of gastroduodenal ulcers the acid inhibitory potential of PPIs will be used mainly to facilitate the eradication of H. pylori. 
